金吾财讯 | 中国生物制药(01177)公布，截至2024年12月31日止年度，归属于母公司持有者盈利35.0亿元(人民币，下同)，同比增长50.08%；每股基本盈利。每股基本盈利19.13分。拟派末期股息每股4港仙。期内，持续经营业务收入288.66亿元，同比增长10.18%。其中，创新产品收入120.6亿元，同比增长21.9%；新产品收入100.9亿元，同比增长25.4%。公告提到，期内，抗肿瘤用药之收入约107.33亿元，同比增长22%；肝病用药之收入约34.38亿元，同比增长10.1%；呼吸系统用药及服务之收入约31.52亿元，同比增长6.2%；外科╱镇痛用药之收入约44.58亿元， 同比增长18.9%；心脑血管用药之收入约21.69亿元，同比减少21%；其他收入49.15亿元，同比增长19.6%。期内，毛利235.3亿元，同比增长10.94%，毛利率81.5%，同比增长0.5个百分点。期内，集团研发总投入约54.88亿元，占本集团收入约19.0%，当中92.7%已计入损益表中，研发费用约50.89亿元。于报告期内，创新药的研发投入占比超过77%，投入金额同比增长约17.2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.